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Abstract 
Background 
The use of diuretics for hypertension has been associated with unfavorable changes in 
cardiovascular risk factors, such as uric acid and glucose tolerance, though the findings in the 
literature are contradictory. 
Methods 
This study investigated whether diuretic use is associated with markers of metabolic and 
cardiovascular risk, such as insulin-resistance and uric acid, in a cohort of adults without 
known diabetes and/or atherosclerotic cardiovascular disease. Nine hundred sixty-nine 
randomly selected participants answered a questionnaire on clinical history and dietary 
habits. Laboratory blood measurements were obtained in 507 participants. 
Results 
Previously undiagnosed type 2 diabetes was recognized in 4.2% of participants who were on 
diuretics (n = 71), and in 2% of those who were not (n = 890; P = 0.53). Pre-diabetes was 
diagnosed in 38% of patients who were on diuretics, and in 17.4% (P < 0.001) of those who 
were not. Multivariate analysis showed that insulin-resistance (HOMA-IR) was associated 
with the use of diuretics (P = 0.002) independent of other well-known predisposing factors, 
such as diet, physical activity, body mass index, and waist circumference. The use of 
diuretics was also independently associated with fasting plasma glucose concentrations (P = 
0.001) and uric acid concentrations (P = 0.01). 
Conclusions 
The use of diuretics is associated with insulin-resistance and serum uric acid levels and may 
contribute to abnormal glucose tolerance. 
Keywords 
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Background 
Hypertension affects up to 60% of patients with type 2 diabetes [1]. It has been reported that 
the concomitance of hypertension and diabetes roughly doubles the risk of cardiovascular 
events [2,3]. Indeed, treatment of hypertension with diuretics has often been attributed to 
increased insulin resistance and accelerated onset of diabetes [4-7]. It has also been reported 
that hypertension often precedes the onset of diabetes, suggesting that anti-hypertensive 
treatment with diuretics may contribute to the development of abnormal glucose tolerance, 
thus offsetting the benefits of the treatment in terms of cardiovascular risk [8,9]. Furthermore, 
the use of diuretics, particularly thiazide, has also been associated with unfavorable 
alterations in other cardiovascular risk factors, such as uric acid and cholesterol 
concentrations [10-13]. 
Despite these negative effects, it has been recommended that treatment of hypertension be 
prioritized and stressed in persons with type 2 diabetes, where first choice agents may include 
thiazide diuretics [14]. In fact, the trend of the use of diuretics, especially that of thiazides, is 
continually increasing [15]. Present guidelines indicate thiazides as first-line therapy in 
hypertension [16], but also suggest that their use as first step drugs be limited in the treatment 
of diabetic patients [17]. Furthermore, the impact of anti-hypertensive treatment with 
diuretics on insulin resistance and glycemia in people without known diabetes and/or 
atherosclerotic diseases is still a matter of debate [14,18-21]. 
Therefore, we investigated the associations between diuretic treatment for hypertension and 
different markers of metabolic and cardiovascular risk in a cohort of randomly selected adults 
without known diabetes and/or atherosclerotic cardiovascular disease. 
Methods 
This observational, cross-sectional study was carried out in Palermo, the largest city in Sicily, 
Italy, with a population of 663,173 from March 28th to April 10th, 2011. Groups composed 
of physicians (n = 5) and dieticians (n = 13) alternated their presence inside the Forum, a 
shopping mall in Palermo, from 9:00 a.m. until 9:00 p.m. There they contacted those 
customers who asked to participate in the study, which had been proposed by means of 
posters at the mall. 
The Forum is the largest shopping center in Palermo, and customers come from all parts of 
the city, suburbs and neighboring areas. Data provided by the Forum administration show 
that the characteristics of their habitual customers were heterogeneous in terms of gender 
(female 65%, male 35%), age (10–54 years 50%, > 55 years 50%), place of residence 
(Palermo 62%, outside of Palermo 38%), education (college graduates = 14%, high school 
graduates = 37%, middle school = 32%, primary school = 17%), and employment status 
(housewife = 40%, retired = 23%, employed = 19%, student = 8%, unemployed = 6%, 
manager/professional = 4%). 
Inclusion criteria were age ≥ 18, and residence in the province of Palermo. Exclusion criteria 
were gastrointestinal or connective diseases, chronic pancreatitis, liver cirrhosis, use of 
nonsteroidal antiinflammatory drugs, corticosteroids, or drugs interfering with coagulation; 
pregnancy or lactation in the past 6 months. In order to encourage the participation of 
younger people without known cardiovascular, metabolic or nutritional diseases, an 
echographic check of the thyroid was also proposed. 
There was no incentive provided to the participants. Participants were asked to present, in the 
morning, in overnight fasting conditions, at the Biomedical Department of the Internal and 
Specialized Medicine’s Laboratory of Clinical Nutrition, at the University of Palermo, in the 
following weeks, and no later than July 15th, 2011, to undergo blood sampling for 
assessment of blood chemistry and hormone values. A blood sample was frozen and stored at 
−80°C, and a sample was treated and stored for subsequent measurements. 
Our institutional ethics committee at the Biomedic Department of Internal and Specialistic 
Medicine approved the study protocol. Each participant signed an approved informed consent 
form. 
Participants were administered a questionnaire on demographic characteristics, the presence 
of chronic disease and pharmacologic treatment, physical activity, including items concerning 
the level of physical activity and its weekly frequency, daily time watching television, on the 
computer, and playing video games. Physical activity was classified as follows: none = no 
significant active physical activity (most of the time spent sitting at home or at work; light = 
short walks (including at work or at home, walking from place to place, and any other 
walking done for recreation, exercise, or leisure for 10–20 minutes/day.); moderate = sports 
activity, including fast walking or bicycling for 20 minutes/day 1–3 times a week; heavy = 
sports activity, including fast walking or bicycling for > 20 minutes/day or heavy work 
activities > 3 times a week). Half-quantitative habitual intakes of different foods during the 
past 12 months were assessed with the Food Frequency Questionnaire (FFQ) [22]. The 
requested information referred to the last year. With a different analysis in the same cohort, 
using an a posteriori approach, we applied a cluster analysis to identify dietary patterns [23], 
a procedure that is based on the intercorrelations among food groups or nutrients. A diet that 
could be defined as unhealthy was identified, and was characterized, by high consumption of 
soft drinks, fried foods, seed oils, cured meats, butter, red meat and sweets; a dietary pattern 
that resembled the Mediterranean diet, defined as healthy, was characterized by high intakes 
of fruit, milk and cheese, olive oil, vegetables, pasta and bread; a third pattern of dietary 
habits was defined as intermediate, and had characteristics that were between the two other 
diets. Type 2 diabetes and pre-diabetes were defined according to the most recent consensus 
statements [24]. In particular, previously undiagnosed type 2 diabetes was defined on the 
basis of a fasting plasma glucose concentration of >125 mg/dl and/or random capillary blood 
glycemia >199 mg/dl and/or glycated hemoglobin >6.4%. Pre-diabetes was diagnosed when 
the fasting plasma glucose concentration was in the range 100–125 mg/dl and/or glycated 
hemoglobin between 5.7-6.4%. The habitual use of anti-hypertensive drugs was investigated 
and questions on the use of diuretics (hydrochlorotiazides, furosemide, spironolactone), beta-
blockers, angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blockers 
(ARBs), calcium channel antagonists (CCA), alpha-blockers, and clonidine were categorized 
as follows: no habitual consumption = 0, habitual consumption = 1. 
Measurements 
Height and body weight were measured with participants lightly dressed and without shoes 
(SECA); the body mass index (BMI) was calculated as body weight (kg)/height2 (m2). Body 
circumferences were measured at the umbilicus (waist circumference) and at the most 
prominent buttock level (hip circumference). 
Systolic and diastolic arterial blood pressure (two measurements obtained at 5-minute 
intervals in seated position) and heart rate were measured by physicians or dietitians with an 
oscillometric device, and according to standardized procedures (Omron M6; Omron 
Healthcare Co; Matsusaka, Mie, Japan). 
Laboratory analysis 
Capillary blood glucose concentrations were randomly assessed using a glucose reflectometer 
(Glucocard G meter; Menarini Diagnostics; Florence, Italy). Fasting plasma glucose (FPG), 
total cholesterol, high-density lipoproteins (HDL) cholesterol, triglycerides, uric acid and 
creatinine concentrations were ascertained with standard clinical chemistry methods 
(Glucosio HK UV; Colesterolo tot. Mod P/D; Colesterolo HDL gen 3 mod P/917; 
Trigliceridi; Acido urico MOD P/917; Creatinina enzimatica; Roche diagnostics, Monza, 
Italy). Basal insulin concentrations (Elecsys insulina; Roche diagnostics; Monza, Italy) and 
glycated hemoglobin (HbA1c; HbA1c gen.3; Roche diagnostics; Monza, Italy) were also 
measured. Low-density lipoprotein (LDL) cholesterol concentration was calculated by means 
of Friedewald’s formula [25]. Estimated glomerular filtration rate (eGFR) was calculated 
according to modification of diet in renal disease study (MDRD) [26]. 
Both the homeostasis model assessment of insulin resistance (HOMA-IR) and the 
homeostasis model assessment of β-cell function (HOMA-β) were calculated as defined by 
Matthews et al. [27]. 
Statistical analysis 
Patient baseline characteristics are reported as frequency (percentage) and mean ± SD or 
median along with lower and upper quartiles. 
Linear regression analyses were done to evaluate factors associated with HOMA-IR, HOMA-
β, fasting plasma concentrations of glucose, and uric acid. The following baseline covariates 
were tested: age, gender, BMI, waist circumference, dietary pattern (Healthy, Intermediate, 
Unhealthy), level of physical activity (light, moderate/heavy or none), use of diuretics (yes or 
no), and use of beta-blockers (yes or no). A two-tailed Wald chi-squared P value of < 0.05 
was considered significant. Multivariate logistic regression analysis was done to evaluate 
factors associated with pre-diabetes, and the following baseline covariates were tested: age, 
gender (male vs. female), BMI, dietary pattern, physical activity level, use of diuretics (yes or 
no), and use of beta-blockers (yes or no). 
All statistical analyses were done using SAS version 9.2 (SAS Institute Inc; Cary, NC, US). 
Results 
A total of 1,231 (465 males and 766 females) participants were evaluated; 270 participants 
were excluded because of the presence of diabetes (type 1 or 2), clinically known 
atherosclerotic diseases (coronary heart disease, previous stroke, carotid or peripheral 
atherosclerosis), chronic renal failure or incomplete anthropometric measurements. 
Laboratory blood measurements were obtained in 507 participants. 
Males constituted 38.2%, 20% of the cohort were current smokers, and 37.3% habitually 
consumed alcohol (at least 5 glasses of wine or beer or superalcoholic a week). The different 
dietary patterns of the participants were as follows: Mediterranean diet = 34.2% (n = 329), 
Unhealthy = 20.8% (n = 200) and Intermediate diet = 45.0% (n = 432). Habitual physical 
activity was classified as “none” in 456 participants (47.4%), “light” in 356 participants 
(37.0%) and “moderate/heavy” in 149 participants (15.6%). The frequency of known 
hypertension was 27.2%. The use of anti-hypertensives was as follows: diuretics = 7.4%, 
beta-blockers = 8.6%, ACEI/ARBs = 15.5%, CAA = 3.4%. The classes of diuretics used 
were as follows: hydrochlorothiazide in 83.1% of patients on diuretic treatment (maximum 
reported daily dose = 25 mg), furosemide in 11.3% of cases (maximum reported daily dose = 
25 mg), and spironolactone in 5.6% (maximum reported daily dose = 50 mg). Statins were 
regularly assumed by 7.1% of participants, and ω-3 fatty acids by 1.6%. Previously 
undiagnosed type 2 diabetes was recognized in 2.2%, and pre-diabetes in 19.7% of the 
cohort. 
Demographic, anthropometric and clinical characteristics of the participants are reported in 
Table 1. Previously undiagnosed type 2 diabetes was identified in 3 (4.2%), pre-diabetes in 
27 (42.2%) of participants with hypertension who were on diuretics (n = 71), and in 28.9% (6 
type 2 diabetics and 49 pre-diabetics) of those with hypertension who were not (n = 190; P = 
0.03). The percentage of males was not significantly different between participants who were 
on diuretics (38%), and those who were not (36.0%; P = 0.65). The metabolic characteristics 
of participants according to the use of diuretics or not are presented in Table 2. The predictors 
of HOMA-IR, HOMA-β, FPG and uric acid concentrations, identified by multiple logistic 
regression analysis, are reported in Tables 3, 4, 5, and 6. In particular, the use of diuretics was 
unfavorably associated with HOMA-IR (P = 0.002), FPG (P = 0.001) and uric acid plasma 
concentrations (P = 0.01). No significant association was observed with the use of beta-
blockers. The predictors of HbA1c were gender (male = 1; estimate = 0.08; P < 0.05), age 
(estimate = 0.01; P < 0.001) and BMI (estimate = 0.01; P < 0.05). Male gender (estimate = 
−100; P < 0.001) and BMI (estimate = −0.56; P < 0.005) were the only significant predictors 
of HDL-cholesterol blood concentrations. Triglyceride levels were significantly predicted by 
Healthy (estimate = −154) or Intermediate (estimate = −132) dietary patterns (P < 0.05), 
gender (male = 1; estimate = 118; P < 0.05), and BMI (estimate = 14.7; P < 0.05). No 
significant association was found among ACEI/ARBs, CAA and other variables considered 
in this study. Multivariate logistic regression analysis demonstrated that only age and waist 
circumference were significantly associated with pre-diabetes (Table 7). 
Table 1 Clinical and biochemical characteristics of the 961 participants 
 Mean ± SD Median (Q1-Q3) 
Age (y) 49 ± 14 50 (38–60) 
Body weight (kg) 73.6 ± 15.9 72.0 (61.6 - 83.5 
BMI (kg/m2) 27.9 ± 5.4 27.2 (24.1-31.0) 
Circumferences   
         Waist (cm) 94.3 ± 14.5 94.0 (85.0 - 103.0) 
         Hip (cm) 104.6 ± 12.3 104.0 (98.0 - 110.0) 
Systolic BP (mmHg) 129 ± 16 128 (118–139) 
Diastolic BP (mmHg) 79 ± 10 78 (72–85) 
Heart rate (beats/min) 74 ± 11 73 (66–81) 
Random capillary blood glucose (mg/dl) 91 ± 12 90 (82–97) 
Blood concentration of n = 507  
         glycated hemoglobin% 5.6 ± 0.4 5.5 (5.3 - 5.8) 
mmol/mol 37.4 ± 4.8 36.6 (34.4 - 39.9) 
         glucose (mg/dl) 88 ± 21 85 (75–97) 
         total cholesterol (mg/dl) 213 ± 39 212 (185–240) 
         hdl cholesterol (mg/dl) 59 ± 15 58 (49–67) 
         triglycerides (mg/dl) 101 ± 49 90 (68–121) 
         ldl cholesterol (mg/dl) 133 ± 36 131 (108–161) 
         uric acid (mg/dl) 5.0 ± 1.4 4.7 (3.9 - 5.9) 
         insulin (µu/ml) 9.6 ± 5.8 8.2 (5.6 - 11.8) 
HOMA-IR 2.2 ± 1.5 1.8 (1.2 - 2.7) 
HOMA-β 141.8 ± 104.5 117.9 (80.0 - 171.4) 
         Creatinine (mg/dL) 0.83 ± 0.21 0.79 (0.69 - 0.94) 
         eGFR-MDRD (mL/min/1.73 m2) 91.8 ± 20.3 90.3 (76.5 – 94.4) 
BMI: body mass index; BP: blood pressure; eGFR: estimated glomerular filtration rate; HDL: high-density lipoproteins; HOMA-IR: 
homeostasis model assessment of insulin resistance; HOMA-β: homeostasis model assessment of β-cell function; LDL: low-density lipoproteins; 
MDRD: modification of diet in renal disease study 
Table 2 Metabolic characteristics of the cohort categorized according to the use of 
Diuretics1 
 Use of Diuretics  
 No Yes P2 
(n = 890) (n = 71)  
Body weight (kg) 72.9 ± 15.5 82.8 ± 17.9 < 0.001 
BMI (kg/m2) 27.5 ± 5.2 31.5 ± 6.2 < 0.001 
Circumference:    
         Waist (cm) 93.6 ± 13.8 102.4 ± 18.3 < 0.001 
         Hip (cm) 104.1 ± 11.7 110.0 ± 16.8 < 0.001 
Systolic BP (mmHg) 129.1 ± 16.2 134.9 ± 17.7 0.005 
Diastolic BP (mmHg) 78.6 ± 9.8 79.6 ± 9.6 0.22 
Heart rate (beats/min) 74.3 ± 11.3 72.5 ± 11.6 0.18 
Random capillary blood glucose (mg/dl) 87 ± 20 95 ± 23 0.001 
Blood concentration of n = 468 n = 39  
         Glycated hemoglobin (%) 5.6 ± 0.43 5.8 ± 0.47 < 0.001 
         (mmol/mol) 37.2 ± 4.7 40.2 ± 5.2  
         Glucose (mg/dL) 90 ± 11 99 ± 13 < 0.001 
         Total cholesterol (mg/dL) 213 ± 39 211 ± 43 0.69 
         HDL cholesterol (mg/dL) 60 ± 15 57 ± 12 0.52 
         Triglycerides (mg/dL) 100 ± 50 111 ± 35 0.008 
         LDL cholesterol (mg/dL) 134 ± 36 132 ± 38 0.71 
         Uric acid (mg/dL) 4.9 ± 1.4 5.8 ± 1.7 < 0.001 
         Insulin (µU/mL) 9.2 ± 5.5 13.2 ± 8.3 < 0.001 
HOMA-I 2.10 ± 1.41 3.31 ± 2.43 < 0.001 
         Creatinine (mg/dL) 0.83 ± 0.21 0.87 ± 0.30 0.93 
GFR - MDRD (mL/min/1.73 m2) 92.4 ± 19.1 90.8 ± 23.9 0.89 
1
 All data are reported as means ± SD. 
2
 Unpaired Student’s t-test. 
BMI: body mass index; BP: blood pressure; GFR: glomerular filtration rate; HDL: high-
density lipoproteins; HOMA-I: homeostasis model assessment of insulin resistance; LDL: 
low-density lipoproteins; MDRD: Modification of Diet in Renal Disease Study. 
Table 3 Linear regression analysis of predictors of HOMA-IR 
 Outcome variable: HOMA-IR 
Parameter Coefficient Standard P 
Estimate Error Chi-Squared 
Diet: healthy vs. non-healthy −0.44 0.18 0.02 
Diet: intermediate vs. non-healthy −0.39 0.17 0.02 
Gender: male vs. female 0.12 0.14 0.40 
Use of diuretics: no vs. yes −0.76 0.24 0.002 
Use of beta-blockers: no vs. yes 0.13 0.22 0.56 
Physical activity: none vs. moderate/heavy 0.47 0.19 0.02 
Physical activity: light vs. moderate/heavy 0.23 0.19 0.23 
Body mass index 0.07 0.02 <0.001 
Waist circumference 0.02 0.006 <0.001 
Age −0.006 0.005 0.25 
HOMA-IR: homeostasis model assessment of insulin resistance. 
Table 4 Linear regression analysis of predictors of HOMA-Β 
 Outcome variable: HOMA-β 
Variable Coefficient Standard P 
Estimate Error Chi-Squared 
Diet: healthy vs. non-healthy −17.36 13.35 0.19 
Diet: intermediate vs. non-healthy −20.31 12.30 0.098 
Gender: male vs. female −24.21 9.96 0.015 
Use of diuretics: no vs. yes 8.34 17.76 0.64 
Use of beta-blockers: no vs. yes −21.33 16.24 0.19 
Physical activity: none vs. moderate/heavy 19.70 14.08 0.16 
Physical activity: light vs. moderate/heavy 25.53 14.08 0.070 
Body mass index 3.99 1.21 <0.001 
Waist circumference 0.03 0.05 0.46 
Age −1.72 0.04 <0.001 
HOMA-β: homeostasis model assessment of β-cell function. 
Table 5 Linear regression analysis of predictors of fasting plasma glucose 
concentrations 
 Outcome variable: Fasting plasma glucose 
Parameter Coefficient Standard P 
Estimate Error Chi-Squared 
Diet: healthy vs. non-healthy −0.17 14.41 0.91 
Diet: intermediate vs. non-healthy 0.44 13.23 0.74 
Gender: male vs. female 38.86 10.74 <0.001 
Use of diuretics: no vs. yes −62.59 19.19 0.001 
Use of beta-blockers: no vs. yes 0.05 17.59 0.98 
Physical activity: none vs. moderate/heavy 17.34 15.12 0.25 
Physical activity: light vs. moderate/heavy −0.56 15.17 0.71 
Body mass index 0.15 0.13 0.26 
Waist circumference 0.12 0.05 0.021 
Age 0.14 0.04 <0.001 
Table 6 Linear regression analysis of predictors of uric acid plasma concentrations 
 Outcome variable: Uric acid 
Parameter Coefficient Standard P 
Estimate Error Chi-Squared 
Diet: healthy vs. non-healthy 0.01 0.16 0.93 
Diet: intermediate vs. non-healthy 0.12 0.14 0.41 
Sex: male vs. female 13.69 0.12 <0.001 
Use of diuretics: no vs. yes −0.53 0.21 0.01 
Use of beta-blockers: no vs. yes −0.27 0.19 0.15 
Physical activity: none vs. moderate/heavy −0.17 0.16 0.30 
Physical activity: light vs. moderate/heavy −0.10 0.16 0.55 
Body mass index 0.023 0.014 0.11 
Waist circumference 0.014 0.005 0.009 
Age 0.01 0.04 0.03 
Table 7 Multivariate-adjusted odds ratios (OR) and 95% confidence intervals (CI) of 
pre-diabetes determined by diuretic use and other factors potentially associated with 
occurrence of Pre-diabetes 
Effect OR1 95% CI 
Age (y) 1.04 1.02 – 1.06 
Gender (M vs. F) 0.68 0.44 – 1.05 
Body Mass Index (kg/m2) 1.03 0.97 – 1.09 
Waist Circumference (cm) 1.02 1.00 – 1.05 
Dietary Pattern   
         Intermediate vs. Mediterranean 1.17 0.74 – 1.85 
         Unhealthy vs. Mediterranean 1.32 0.73 – 2.37 
Physical activity level:   
         Light vs. none 0.87 0.56 – 1.36 
         Moderate/heavy vs. none 0.80 0.42 – 1.52 
Use of Diuretics: yes vs. not 1.86 0.88 – 3.93 
Use of Beta-blockers: yes vs. not 0.80 0.40 – 1.61 
1The following baseline covariates were tested: age, gender (male vs. female), body mass 
index, waist circumference, dietary pattern (unhealthy, intermediate, Mediterranean), 
physical activity level (none, light and moderate/heavy), use of diuretics (yes vs. not), use of 
beta-blockers (yes vs. not). 
Discussion 
This cross-sectional study suggests that the use of diuretics is independently associated with a 
diabetogenic metabolic pattern. First, insulin-resistance expressed as HOMA-IR was 
associated with the use of diuretics independent of other well-known influencing factors, 
such as diet, physical activity, BMI and waist circumference. Second, FPG, which is strongly 
influenced by neoglucogenesis, a biochemical pathway that is enhanced by insulin resistance, 
was independently associated with the use of diuretics. These results are of interest given that 
participants with known diabetes were excluded from the study. Abnormal glucose tolerance 
and hypertension are often associated in the context of the metabolic syndrome, and 
recognized as common features of insulin-resistance [1]. However, given the results of our 
multivariate analysis, we are inclined to exclude that the association of diuretic use with 
HOMA-IR and FPG is a consequence of the frequent association between diabetes and 
hypertension. Indeed, no other antihypertensive treatment, including beta-blockers, 
ACEI/ARBs and CAA, was associated with these variables. Also, we found that the 
frequency of previously unknown type 2 diabetes and pre-diabetes was significantly higher in 
those patients with hypertension who were on diuretic treatment than in those who were not, 
however, the use of diuretics was not independently associated with pre-diabetes. No 
association was found between diuretic use and HOMA-B, suggesting that the possible 
diabetogenic effect of these drugs does not involve the beta-cell function. Because the doses 
of diuretics habitually consumed by patients in our study were low, our results do not confirm 
those studies that found that low dosage diuretics have no significant effect on glucose 
homeostasis [10,28]. Among the mechanisms by which diuretics can induce insulin 
resistance, hypokalemia consequent to diuretics use has been considered principally 
responsible for impaired insulin sensitivity [7,28] despite the fact that the unfavorable effect 
on glucose homeostasis persists, even if mitigated, when oral potassium is supplemented 
[29]. Unfortunately, serum potassium concentrations were not measured in this study. 
Our study also confirms that the use of diuretics is independently associated with uric acid 
levels, a well-known effect in connection with insulin resistance. Elevated serum uric acid 
levels are commonly seen in association with glucose intolerance, hypertension and 
dyslipidemia, a cluster of metabolic and hemodynamic disorders that characterizes the 
metabolic syndrome [30-34]. Hyperinsulinemic, insulin-resistant people have a decreased 
clearance of uric acid in the renal proximal tubule that is not insulin resistant [35]. However, 
other mechanisms may explain the hyperuricemic effect of diuretics. Volume depletion 
consequent to diuretic treatment reduces renal blood flow, with consequent urate 
underexcretion. Indeed, diuretics influencing the ion exchange proteins at the proximal tubule 
lumen membrane in the kidney increase both sodium and urate reabsorption [36]. Despite the 
fact that the role of uric acid as an independent contributor to cardiovascular risk remains 
uncertain [13,37], different mechanisms induced by uric acid have been proposed as agents 
that may be responsible for unfavorable cardiovascular effects, including enhanced platelet 
aggregation [38], inflammation and endothelial dysfunction [39]. The association between 
use of diuretics and serum uric acid concentrations is not of secondary importance. Treatment 
of hypertension with diuretics raises uric acid concentrations, though there is evidence that 
increased uric acid concentrations may themselves contribute to inducing hypertension [37]. 
Therefore, the relationship between diuretic use, hypertension, insulin-resistance and 
abnormal glucose tolerance may be more complex, and it is possible that diuretic treatment 
may partially offset the benefits of reduction of blood pressure. Kivity et al. [40] recently 
reported that after a follow-up of 4.8 years, serum uric acid was independently associated 
with cardiovascular disease in healthy people, especially in women. In the WORKSITE 
study, an increase in serum uric acid was independently associated with cardiovascular events 
[41]. Moreover, in the SHEP trial, the reduction in coronary events through treatment with a 
diuretic was not be observed when serum uric acid increased more than 60 µmol/L during 
treatment [42]. These studies suggest that hyperuricemia consequent to diuretic use may, in 
part, offset the benefits of diuretics in preventing cardiovascular complications of 
hypertension. 
Despite these findings, our study should be considered with caution given that diuretics have 
proven extremely useful in the prevention of stroke and cardiovascular events in both 
diabetics and non-diabetics [42,43]. Also, diuretics did not increase the risk of diabetes in a 
longitudinal observation that included 458 patients [44]. This study has several limitations. 
First, a larger cohort may have allowed for more robust conclusions. The sample size was 
relatively small, and only about 53% of the cohort had complete laboratory measurements, 
this may have blunted the statistical power of the observed associations. Given the cross-
sectional design of the study, we cannot exclude the possibility of residual confounding. We 
did not perform an oral glucose tolerance test, which is the gold standard for classifying 
individual glucose tolerance levels [24], thus possibly underestimating the frequency of pre-
diabetes and diabetes in our cohort. Nonetheless, the combined use of FPG and HbA1c (we 
also included random glycemia) is acknowledged as a sensitive and specific screening tool 
for identifying individuals with diabetes and impaired glucose tolerance [45,46]. We did not 
enroll a representative cohort of the Palermo population and some bias might be associated 
with the sampling technique. However, the composition of the cohort we recruited was 
similar to that reported for the shopping mall customers. In addition, having also offered the 
possibility of a thyroid echography check likely prompted younger people without known 
cardiovascular, metabolic or nutritional clinical problems to take part in the study. More 
women than men participated, though this is a common problem in all trials, screening and 
epidemiological studies. Our study does, however, have some merits. This is a single center 
study, and the modality of participant recruitment likely allowed for the selection of a cohort 
that was representative of the population. Due to the small number of participants, we were 
not able to distinguish the effects of each single category of diuretics, and thus have to 
propose a unique class effect. Indeed, for the same reasons, we could not distinguish 
differences among different doses of diuretics. However, our study also has the merit of 
having considered both the effects on uric acid concentrations and insulin resistance. It is 
worth noting that we measured all variables potentially influencing the outcomes of the study, 
including anthropometric measurements, dietary factors and habitual physical activity. In 
addition, the enrollment of participants occurred within a short time, in the same season, and 
a small, select group of dieticians administered questionnaires face-to-face, all of which may 
have contributed to increasing the quality of the data. 
Conclusions 
We can confirm that use of diuretics, even at low dosages, is associated with insulin 
resistance and increased serum uric acid levels in adults without known diabetes and/or 
cardiovascular diseases. We also found evidence that abnormal glucose tolerance is 
associated with use of diuretics. However, only longitudinal interventional studies can 
elucidate the effective influence of diuretics on global cardiovascular risk. 
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